Case Kaidi (Shanghai) Pharmaceutical Technology Co., Ltd.

To evaluate the safety, tolerability and preliminary efficacy of different doses of CS0159 tablets (hereinafter referred to as CS0159) in patients with primary sclerosing cholangitis (PSC)

1) Quantitatively analyze the total radioactivity in excreta after oral administration of [14C]CS0159 to healthy male subjects, and obtain the cumulative excretion rate and main excretion pathway of radioactivity in the human body; 2) Identify the main metabolites in the human body after oral administration of [14C]CS0159 to healthy male subjects, and determine the main biotransformation pathways and main metabolites (close to or greater than 10% of the total radioactivity AUC); 3) Investigate the distribution of total radioactivity in whole blood and plasma and the pharmacokinetics of total radioactivity in plasma after a single oral administration of [14C]CS0159 to healthy male subjects.